Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

• Published in: Leukemia & lymphoma Vol. 62; no. 11; pp. 2727 - 2736
• Main Authors: Boluda, Blanca, Martínez-Cuadrón, David, Algarra, Lorenzo, Cano, Isabel, Sayas, María J., Acuña-Cruz, Evelyn, Blanco, Albert, Marco-Ayala, Javier, DeLapuerta, Rosalía, Díaz-González, Álvaro, Tormo, Mar, Rodríguez-Veiga, Rebeca, García, Raimundo, Piñana, José L., López-Pavía, María, Barragán, Eva, Amigo, María L., Sargas, Claudia, López, Aurelio, Solana-Altabella, Antonio, Gil, Cristina, Megías-Vericat, Juan Eduardo, Sanz, Miguel A., Montesinos, Pau
• Format: Journal Article
• Language: English
• Published: Taylor & Francis 19.09.2021
• Subjects: FLT3mut AML; real-world; relapse/refractory
• ISSN: 1042-8194; 1029-2403; 1029-2403
• DOI: 10.1080/10428194.2021.1938031

We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy (n = 25, 74%), and supportive care (n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy (n = 63, 56%), hypomethylating agent (n = 7, 6%), low-dose cytarabine-based (n = 8, 7%), clinical trial (n = 16, 14%) and supportive care (n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 30% with non-intensive p = 0.005). Median overall survival since first R/R was 5.8 months, and 16.3 months in subjects receiving an allo-HSCT in CR/CRi after first salvage (vs 3.8 in the remaining patients p < 0.0001). Clinical outcomes of R/R FLT3mut AML remain unsatisfactory. Inclusion in clinical trials and expanding options could lead to improved outcomes.